Vir Biotechnology reports Q3 2026 results, announces Fast Track for VIR‑5500 and $90 M Gilead partnership
Vir Biotechnology released its third‑quarter 2026 financials and corporate update. The company said topline data from the Phase 3 ECLIPSE‑1 hepatitis‑delta trial are expected in the fourth quarter of 2026, and that its oncology candidate VIR‑5500 received FDA Fast Track designation with pivotal trials slated for 2027. Vir also disclosed a collaboration with Gilead that provides a $90 million upfront cash payment.
Why it matters
The company stated its cash, cash equivalents and investments will fund operations into the second half of 2028, giving it runway to complete the upcoming trials (the 8‑K notes). The Fast Track designation could accelerate regulatory review of VIR‑5500, potentially adding value for shareholders (the 8‑K notes). The $90 million upfront from Gilead improves short‑term liquidity (the 8‑K notes).
Key facts
- 1Topline data from the pivotal Phase 3 ECLIPSE‑1 trial are expected in the fourth quarter of 2026. sec.gov
- 2U.S. FDA granted Fast Track designation to VIR‑5500 for late‑line metastatic castration‑resistant prostate cancer. sec.gov
- 3Vir entered a collaboration and license agreement with Gilead that includes a $90 million upfront cash payment. sec.gov
- 4Cash, cash equivalents and investments were approximately $901.3 million as of September 30 2026, excluding the $90 million upfront from the Gilead collaboration. sec.gov
- 5Non‑GAAP diluted earnings per share for Q3 2026 were –$0.57. seekingalpha.com
- 6Q3 2026 revenue was –$188 thousand and net loss was –$96.25 million. tradingview.com
Open questions
- Material 1 reports cash and investments of approximately $1.74 billion, while material 2 reports $901.3 million excluding the $90 million upfront; the differing figures reflect different inclusion bases.
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.